FIELD: obstetrics and gynecology.
SUBSTANCE: over a 2-5 day period, 2.0 ml of Ginipral is administered once a day intravenously in a drop-by-drop manner followed by intravenously drop-by-drop administered 30-40 min later 2.0 ml of Instenone and, in the evening, 1 dragee Instenone orally. Afterwards, Instenone and Ginipral are administered orally: the former in dose of 1 dragee thrice a day with meal and the latter in dose of 1 pellet four times a day after meal until symptoms of the risk of prevention of pregnancy disappear.
EFFECT: prolonged pregnancy and prevented premature birth, which favors reduced irritation, normalized tonus, contractive activity of uterus, and improved psychic and emotional state of women.
2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING PATHOLOGICAL PRELIMINARY PERIOD | 2001 |
|
RU2203091C2 |
| METHOD FOR TREATING PRELIMINARY PATHOLOGICAL PERIOD CASES | 2004 |
|
RU2292883C2 |
| METHOD OF REMODELING OF THREATENED PRETERM LABOR | 2017 |
|
RU2647227C1 |
| METHOD FOR TREATING PRELIMINARY PATHOLOGICAL PERIOD CASES | 2004 |
|
RU2292882C2 |
| METHOD OF TREATING THREATENING MISCARRIAGE IN 2-3 TRIMESTER OF PREGNANCY | 2012 |
|
RU2514542C1 |
| METHOD FOR PREPARING FOR PARTURITION PROCESS IN PREGNANT WOMEN OF HIGH RISK ON THE DEVELOPMENT OF PARTURIENT ABNORMALITIES | 2005 |
|
RU2294748C2 |
| METHOD FOR PREDICTING FETAL STATE DURING PARTURITION | 2005 |
|
RU2294136C2 |
| METHOD FOR PREPARING HIGH-RISK GROUP PREGNANT WOMEN FOR DELIVERY BECAUSE OF THE DEVELOPMENT OF ABNORMALITIES OF BIRTH ACTIVITY | 2004 |
|
RU2268057C1 |
| METHOD FOR TREATING ABNORMALITY OF UTERINE CONTRACTILE ACTIVITY AT PARTURITION | 2005 |
|
RU2294201C2 |
| METHOD OF TREATING THREATENED PREGNANCY | 2009 |
|
RU2417109C2 |
